Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E (specifically, alpha-tocopherol and its derivatives such as alpha-tocopherol succinate) has been studied for its potential role in the prevention and treatment of arteriosclerosis (atherosclerosis), primarily due to its antioxidant properties. The rationale is that oxidative modification of low-density lipoprotein (LDL) contributes to the development of atherosclerotic plaques, and antioxidants like vitamin E may help prevent this process. Early observational studies and animal research suggested that higher vitamin E intake was associated with reduced cardiovascular risk. However, large randomized controlled trials (RCTs) in humans, such as the HOPE and ATBC studies, have generally not shown significant benefit of vitamin E supplementation in reducing the incidence of cardiovascular events or progression of arteriosclerosis. Some meta-analyses have even suggested potential harm at high doses. Despite these findings, vitamin E continues to be used in some supplements marketed for cardiovascular health. In summary, while there is a scientific rationale and some early supportive evidence, high-quality clinical trial data do not robustly support vitamin E supplementation for arteriosclerosis, and its use is not routinely recommended by major cardiovascular guidelines.

More about Vitamin E (alpha-tocopherol succinate)
More about Arteriosclerosis

Other ingredients used for Arteriosclerosis

Other health conditions supported by Vitamin E (alpha-tocopherol succinate)

Products containing Vitamin E (alpha-tocopherol succinate)